SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.01), $0.02 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $14.14 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.